Our group is interested in advancing clinical research – especially in type 1 diabetes, but also in the context of other immune-mediated diseases.
We focus on development and utilization of rigorous analytical methods to identify immune features associated with clinical outcomes, including progression of disease and response to therapy. We also seek to implement cutting-edge clinical trial designs, including use of short-term interventions with mechanistic outcomes and novel considerations of trial outcome measures.
With Drs. Lord and Smithmyer, Dr. Speake oversees BRI’s biorepositories. Her group collaborates with other academic researchers worldwide and facilitates collaborations with biotech and pharma companies. She also oversees BRI’s Clinical Core Laboratory, which is responsible for sample processing and storage for the hundreds of thousands of samples currently stored in the BRI biorepository.

Cate Speake, PhD
Lab Members

Christine Bender, PhD

Linda Dement

Bradford Dimos, PhD

Rachel Hartley, PMP

Pamela Miranda

Thien-Son Nguyen, BS

Sarah Robinson

Jessica Sarratt

Megan Smithmyer, PhD

Cameron Willman
Research Projects

Rigor and Reproducibility in T1D Biomarker Research

The Sound Life Project

Understanding Progression of T1D
Featured Publications
-
Jun 2025
Longitudinally stable T cell function and innate immune activation distinguish healthy adult immunotypes.
Sci Transl MedSmithmyer ME, Hu A, Dufort MJ, Hocking AM, Wiedeman AE, Fasano KJ, Torgerson TR, Skene PJ, Reading J, Li X, Gong Q, Long SA, Lacy-Hulbert A, Gustafson CE, Buckner JH, Speake C, members of the BRI Sound Life Project Team, BRI Sound Life Project Team -
Nov 2023
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.
Nat CommunYlescupidez A, Bahnson HT, O'Rourke C, Lord S, Speake C, Greenbaum CJ -
Mar 2023
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Nat CommunJaycox JR, Lucas C, Yildirim I, Dai Y, Wang EY, Monteiro V, Lord S, Carlin J, Kita M, Buckner JH, Ma S, Campbell M, Ko A, Omer S, Lucas CL, Speake C, Iwasaki A, Ring AM -
Oct 2022
IL-6-targeted therapies directed to cytokine or receptor blockade drive distinct alterations in T cell function.
JCI InsightSpeake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH -
Apr 2020
Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals.
Diabetes CareSo M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C